Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Receives Average Rating of “Hold” from Analysts

Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating) have been given an average recommendation of “Buy” by the eleven research firms that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $148.78.

Several equities research analysts have issued reports on the company. Cantor Fitzgerald downgraded Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a report on Wednesday. HC Wainwright downgraded Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a report on Wednesday. Morgan Stanley lowered their price target on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Mizuho boosted their price target on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the company a “buy” rating in a report on Thursday, March 3rd. Finally, SVB Leerink downgraded Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and set a $150.00 price target for the company. in a report on Wednesday.

BHVN stock traded up $0.40 during midday trading on Friday, hitting $141.00. 5,100,679 shares of the company’s stock were exchanged, compared to its average volume of 2,314,907. Biohaven Pharmaceutical has a 12-month low of $65.68 and a 12-month high of $151.51. The firm has a 50 day moving average price of $113.74 and a 200-day moving average price of $121.21. The stock has a market capitalization of $9.94 billion, a price-to-earnings ratio of -11.91 and a beta of 1.20.

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($2.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by ($0.45). During the same period in the prior year, the firm posted ($4.21) earnings per share. On average, sell-side analysts forecast that Biohaven Pharmaceutical will post -9.28 earnings per share for the current fiscal year.

In related news, CAO George C. Clark sold 4,200 shares of the company’s stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $141.50, for a total transaction of $594,300.00. Following the completion of the transaction, the chief accounting officer now directly owns 4,065 shares in the company, valued at approximately $575,197.50. The sale was disclosed in a document filed with the SEC, which is available through this link. 12.40% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its position in Biohaven Pharmaceutical by 14.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 61,683 shares of the company’s stock worth $8,567,000 after acquiring an additional 7,791 shares during the period. Two Sigma Advisers LP acquired a new position in Biohaven Pharmaceutical during the 3rd quarter worth $5,404,000. Montag A & Associates Inc. acquired a new position in Biohaven Pharmaceutical during the 3rd quarter worth $96,000. Balyasny Asset Management LLC acquired a new position in Biohaven Pharmaceutical during the 3rd quarter worth $4,785,000. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Biohaven Pharmaceutical by 40.3% in the third quarter. Teacher Retirement System of Texas now owns 9,254 shares of the company’s stock valued at $1,285,000 after buying an additional 2,660 shares during the period. Institutional investors own 88.03% of the company’s stock.

About Biohaven Pharmaceutical (Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Stories

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.